| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
ChemoCentryx Inc (NASDAQ: CCXI)
CCXI Technical Analysis
5
| As on 20th Oct 2022 CCXI SHARE Price closed @ 51.99 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 23.83 & Strong Buy for SHORT-TERM with Stoploss of 13.05 we also expect STOCK to react on Following IMPORTANT LEVELS. |
CCXISHARE Price
| Open | 51.99 | Change | Price | % |
| High | 51.99 | 1 Day | 0.00 | 0.00 |
| Low | 51.99 | 1 Week | 0.07 | 0.13 |
| Close | 51.99 | 1 Month | 0.49 | 0.95 |
| Volume | N/A | 1 Year | 24.50 | 89.12 |
| 52 Week High 51.98 | 52 Week Low 9.59 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| CCXI Daily Charts |
CCXI Intraday Charts |
Whats New @ Bazaartrend |
CCXI Free Analysis |
|
|
CCXI Important Levels Intraday
| RESISTANCE | 51.99 |
| RESISTANCE | 51.99 |
| RESISTANCE | 51.99 |
| RESISTANCE | 51.99 |
| RESISTANCE | 51.99 |
| RESISTANCE | 51.99 |
| RESISTANCE | 51.99 |
| RESISTANCE | 51.99 |
CCXI Forecast April 2024
| 4th UP Forecast | 62.15 |
| 3rd UP Forecast | 58.89 |
| 2nd UP Forecast | 56.88 |
| 1st UP Forecast | 54.86 |
| 1st DOWN Forecast | 49.12 |
| 2nd DOWN Forecast | 47.1 |
| 3rd DOWN Forecast | 45.09 |
| 4th DOWN Forecast | 41.83 |
CCXI Weekly Forecast
| 4th UP Forecast | 54.75 |
| 3rd UP Forecast | 53.86 |
| 2nd UP Forecast | 53.32 |
| 1st UP Forecast | 52.77 |
| 1st DOWN Forecast | 51.21 |
| 2nd DOWN Forecast | 50.66 |
| 3rd DOWN Forecast | 50.12 |
| 4th DOWN Forecast | 49.23 |
CCXI Forecast2024
| 4th UP Forecast | 133.83 |
| 3rd UP Forecast | 107.58 |
| 2nd UP Forecast | 91.36 |
| 1st UP Forecast | 75.14 |
| 1st DOWN Forecast | 28.84 |
| 2nd DOWN Forecast | 12.62 |
| 3rd DOWN Forecast | -3.6 |
| 4th DOWN Forecast | -29.85 |
ChemoCentryx Inc ( NASDAQ USA Symbol : CCXI )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
CCXI Business Profile
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California. Address: 835 Industrial Avenue, San Carlos, CA, United States, 94070
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service